A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 26, 2024

Primary Completion Date

March 31, 2026

Study Completion Date

March 31, 2026

Conditions

Netherton Syndrome

Interventions

DRUG

BCX17725

BCX17725 for injection

DRUG

Placebo

Placebo for injection

Trial Locations (3)

RECRUITING

Investigative site, Indianapolis

RECRUITING

Investigative site, Sydney

RECRUITING

Investigative site, Brisbane